Drawing for QUANTUM ADC BY ONCOMATRYX

USPTO serial 79458009

QUANTUM ADC BY ONCOMATRYX

Reviewed by CopyMark Law Group

Status 640Office Action
Filing date
Status date
Registration date
—
Examiner
TWOHIG, SHANNON MARIE
Law office
TMEG LAW OFFICE 105

What this means

The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.

Status 640: Status 640 means the examining attorney has prepared a non-final Office Action but it has not been mailed or e-mailed yet. The action should appear in TSDR soon, and a response deadline will start once it is issued.

Need help with QUANTUM ADC BY ONCOMATRYX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Get help with this Office Action, set up monitoring, or talk with CopyMark.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Justin R. Young

Justin R. Young DTL Ltd.134 N La Salle StSuite 1050Chicago, IL 60602

Goods and services

ClassDescriptionStatusFirst use
001Reagents for medical research; regulatory proteins for scientific use; reagents for chemical analyses; diagnostic reagents for scientific use; laboratory reagents for scientific use; reagents for use in immunoserology; chemical products for use in industry and science.ACTIVE—
005Reagents for medical diagnosis; reagents for use in diagnostic tests for medical purposes; diagnostic products for medical use; diagnostic testing materials for medical use; antibodies; pharmaceutical products; chemical preparations for medical use.ACTIVE—
010Tracing material analyzers for medical use in diagnostics; diagnostic testing apparatus for use in immunoassay procedures [medical]; diagnostic testing instruments for use in immunoassay procedures [medical]; surgical apparatus and instruments for medical use.ACTIVE—
042Chemical research and analysis services; research and development of new products for third parties; preparation of biological samples for use in testing and analysis in research laboratories; analysis of the behavior of chemical substances; scientific and technological services; biomedical research services; scientific and industrial research services; medical and pharmacological research services.ACTIVE—
044DNA or RNA testing for cancer diagnosis and prognosis; medical diagnostic services [testing and analysis]; medical analysis services provided by medical laboratories for diagnostic and therapeutic purposes.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 21, 2026RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Oct 20, 2026CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 13, 2026DOCKASSIGNED TO EXAMINER—
Oct 2, 2026ECDRTEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS—
Oct 2, 2026ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 2, 2026REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 2, 2026CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 2, 2026COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Sep 10, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Sep 10, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Sep 10, 2026REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance